BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-334@pharmaconomics
DTSTAMP:20260707T030117Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:IRWD Phase 3 — apraglutide (estimated date)
DESCRIPTION:Phase 3 trial results for apraglutide in short bowel syndrome (SBS) with intestinal failure (SBS-IF) are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1446847/000110465926056656/tm267094d1_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/334
URL:https://pharmaconomics.com/e/334
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IRWD catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR